Dianthus Therapeutics, Inc. /DE/ (DNTH) Earnings
Dianthus Therapeutics, Inc. /DE/'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 4, 2026
From the latest earnings 8-K
Revenue • FY2025
$2.04M
▼ 67.3%YoY
Diluted EPS • FY2025
-$4.20
▼ 64.7%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from DNTH's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.04M | -$162.34M | — | -$4.20 | -$129.27M | -8739.3% | -67.3% |
| FY2024 | $6.24M | -$84.97M | — | -$2.55 | -$78.28M | -1633.7% | +120.6% |
| FY2023 | $2.83M | -$43.55M | — | -$8.45 | -$36.97M | -1704.7% | — |
| FY2022 | — | -$28.48M | — | -$32.57 | -$29.21M | — | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 4, 2026 | 8-K (2.02) | 0001690585-26-000039EDGAR |
| Aug 4, 2026 | 8-K (2.02) | 0001690585-26-000033EDGAR |
| May 5, 2026 | 8-K (2.02) | 0001690585-26-000021EDGAR |
| Mar 9, 2026 | 8-K (2.02) | 0001193125-26-097555EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0001193125-26-009898EDGAR |
| Nov 5, 2025 | 8-K (2.02) | 0001193125-25-266867EDGAR |
| Oct 16, 2025 | 8-K (2.02) | 0001193125-25-240858EDGAR |
| Aug 7, 2025 | 8-K (2.02) | 0000950170-25-105002EDGAR |
Never miss a DNTH filing.
Get an email when DNTH files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 5, 2026Source: SEC EDGAR.